Reviewed Mar 2026 | PubMed sources
Active Market
This comparison can feed directly into US-first legal, provider, and cost workflows.

Retatrutide vs Survodutide: Head-to-Head Comparison

Both are investigational next-generation peptides for obesity. Retatrutide is a triple agonist (GIP/GLP-1/glucagon) with up to 24.2% weight loss — the highest ever reported. Survodutide is a dual agonist (GLP-1/glucagon) with up to 19% weight loss and strong MASH data. Neither is FDA-approved yet.

Side-by-Side Comparison

DimensionRetatrutideSurvodutide
Evidence LevelLevel B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA StatusNot approved; Eli Lilly Phase 3Not approved; Boehringer Ingelheim Phase 3
Weight Loss EfficacyUp to 24.2% (Phase 2 at 48 weeks)Up to 19% (Phase 2 at 46 weeks)
MechanismTriple agonist: GIP + GLP-1 + glucagonDual agonist: GLP-1 + glucagon
Liver Fat / MASH BenefitSignificant liver fat reduction observedSignificant liver fat reduction; dedicated MASH trials
Diabetes EfficacyHbA1c reduction up to 2.16% in Phase 2Glycemic improvements observed; less diabetes-specific data
Evidence Level
Retatrutide
Level B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)
Survodutide
Level B — Phase 2 data; Phase 3 ongoing (SYNCHRONIZE)
FDA Status
Retatrutide
Not approved; Eli Lilly Phase 3
Survodutide
Not approved; Boehringer Ingelheim Phase 3
Weight Loss Efficacy
Retatrutide
Up to 24.2% (Phase 2 at 48 weeks)
Survodutide
Up to 19% (Phase 2 at 46 weeks)
Mechanism
Retatrutide
Triple agonist: GIP + GLP-1 + glucagon
Survodutide
Dual agonist: GLP-1 + glucagon
Liver Fat / MASH Benefit
Retatrutide
Significant liver fat reduction observed
Survodutide
Significant liver fat reduction; dedicated MASH trials
Diabetes Efficacy
Retatrutide
HbA1c reduction up to 2.16% in Phase 2
Survodutide
Glycemic improvements observed; less diabetes-specific data

Peptide Overviews

Retatrutide

BHuman Studies

Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.

Weight LossNot Approved
View full Retatrutide profile →

Survodutide

BHuman Studies

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).

Weight LossNot Approved
View full Survodutide profile →

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Retatrutide vs Survodutide: FAQ